Voting Rights and Shares Capital of the Company

Rhea-AI Summary

Nanobiotix (Euronext Paris, Nasdaq: NBTX) published its monthly disclosure of share capital and voting rights in line with French regulatory requirements. As of July 31, 2026, the company reports 50,833,462 shares outstanding.

Total voting rights amount to 54,534,179 theoretical (“gross”) and 54,512,061 exercisable (“net”) voting rights. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, focused on physics-based therapeutic approaches in oncology and other indications.

Market Context

The prior July voting-rights disclosure was followed by -4.41% over 24 hours, adding a company-speci...

Analysis

The prior July voting-rights disclosure was followed by -4.41% over 24 hours, adding a company-specific historical reference to this routine update. Relatively low short positioning provided limited squeeze-risk context; disclosure-driven volatility remained a risk.

Key Figures

Shares outstanding: 50,833,462 shares Theoretical voting rights: 54,534,179 rights Exercisable voting rights: 54,512,061 rights

3 metrics

Shares outstanding 50,833,462 shares July 31, 2026

Theoretical voting rights 54,534,179 rights July 31, 2026

Exercisable voting rights 54,512,061 rights July 31, 2026

Historical Context

5 past events · Latest: Jul 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 30	Voting rights disclosure	Neutral	-4.4%	Reported June share capital and theoretical and exercisable voting rights
Jun 05	Voting rights disclosure	Neutral	+1.2%	Reported May share capital and theoretical and exercisable voting rights
Jun 02	Operational update	Positive	-4.2%	Reported offering proceeds, clinical data, protocol amendment, and cash position
Jun 02	Index inclusion	Positive	-3.3%	Joined the Euronext Tech Leaders segment and index
May 26	Global offering	Negative	-0.7%	Closed global offering raising approximately $100 million in gross proceeds

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed negative reactions after two positive updates, while voting-rights disclosures produced mixed reactions and the offering reaction aligned negatively.

Key Terms

theoretical voting rights, exercisable voting rights, shares held in treasury

3 terms

theoretical voting rights regulatory

"The total number of theoretical (or “gross”) voting rights is used as the basis"

Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.

exercisable voting rights regulatory

"The total number of exercisable at a shareholders’ meeting (or “net”) voting rights"

Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.

shares held in treasury financial

"without taking into account shares for which voting rights have been suspended as shares held"

Shares held in treasury are stock a company issued and later repurchased, keeping those shares in its own ‘storage’ where they typically don’t vote or receive dividends. For investors this matters because treasury shares reduce the number of shares held by the public—potentially lifting per‑share earnings and changing ownership percentages—and the company can later reissue or retire them, which affects supply and possible dilution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
July 31, 2026	50,833,462	54,534,179	54,512,061

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

^{__________________
1} The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Attachment

• 2026-08-25 -- NBTX -- Voting Rights & Shares Capital -- FINAL

FAQ

How many shares are outstanding for Nanobiotix (NBTX) as of July 31, 2026?

Nanobiotix reports 50,833,462 shares outstanding as of July 31, 2026. According to Nanobiotix, this figure reflects the total number of issued shares used as the basis for calculating both theoretical and exercisable voting rights under French regulations.

What are the total voting rights for Nanobiotix (NBTX) on July 31, 2026?

Nanobiotix reports 54,534,179 theoretical voting rights and 54,512,061 exercisable voting rights as of July 31, 2026. According to Nanobiotix, theoretical rights include suspended votes, while exercisable rights exclude shares with suspended voting rights such as treasury shares.

What is the difference between theoretical and exercisable voting rights for Nanobiotix (NBTX)?

Theoretical voting rights include all shares with attached votes, even if suspended. According to Nanobiotix, exercisable voting rights exclude shares where voting rights are suspended, such as treasury shares, and represent the votes that can actually be cast at shareholders’ meetings.

Why did Nanobiotix (NBTX) publish voting rights and share capital information on August 25, 2026?

Nanobiotix published its voting rights and share capital data to comply with French market regulations. According to Nanobiotix, the disclosure follows Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation for market transparency.

On which markets is Nanobiotix (NBTX) listed and what are its key identifiers?

Nanobiotix is listed on Euronext Paris and the Nasdaq Global Select Market under the ticker NBTX. According to Nanobiotix, its ISIN is FR0011341205, with Bloomberg code NANO:FP and Reuters code NANO.PA for market reference.

What type of company is Nanobiotix (NBTX) according to its August 25, 2026 disclosure?

Nanobiotix describes itself as a late-stage clinical biotechnology company focused on physics-based therapeutic approaches. According to Nanobiotix, it owns more than 30 patent families across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.